Q2 2021

Filed Aug 9, 2021 · 10-Q · 40 days after period end · 0001564590-21-042657

Q2 2021 · 10-Q

Revenue

$379.00K

±0.0% vs Q2 2020

Net Income

-$22.91M

N/M vs Q2 2020

EPS Diluted

-$0.44

N/M vs Q2 2020

Operating Income-$22,334,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2021	Q2 2020	Q2 2019	Q2 2018
Revenue	$379.00K	$379.00K	$379.00K	$379.00K
Net Income	-$22.91M	-$17.06M	-$14.92M	-$18.39M
EPS Diluted	-$0.44	-$0.42	-$0.47	$0.74

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR